Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
Location: University Health Network
Generously funded by the Richard Motyka Brain Tumour Research Fellowship
Glioblastoma (GBM) is a brain tumour with a patient median survival period of 15 months, a clinical outcome that has remained unchanged over the last 40 years. Recent molecular profiling efforts have established that DNA mutations in a gene called IDH1/2 result in improved patient survivals beyond 5 years. However, such DNA mutations only represent a minority of GBM patients (5-10%) and thus novel molecular approaches are needed to further subclassify and provide more superior prognostic and therapeutic approaches. I will use state of the art mass spectrometry-based global proteomic analysis to define GBM subgroups based on their protein make-up. Analysis of epidemiologically defined group of 200 primary GBM samples of varying patient outcomes, from short to long term survivors, will be used to define proteomic diagnostic predictors of patient survival, in tumours lacking definitive genomic mutation classifications. Furthermore, identification of proteomic signatures with more refined GBM classifications will establish a platform for assessing pharmacologic effectiveness on proliferation and cancer stem cell identities of tissue culture models of GBM. Collectively, our research proposal aims to yield novel molecular predictors of patient outcomes that offer an avenue for more patient-specific pharmacological interventions and ultimately result in improved GBM patient treatment.
"Being awarded the Richard Motyka Brain Tumour Research Fellowship means that I can continue to pursue my passionate career of finding better treatment options for glioblastoma brain tumour patients.
Although genomics-based breakthroughs have made moderate impacts on improving patient diagnosis, overall glioblastoma survival rates have remained stagnant over the last twenty years.
With the generous support of this fellowship I can focus on utilizing the newest available proteomics technologies to further understand this devastating cancer and improve patient outcomes as a result. Indeed, mass spectrometry-based proteomic efforts have shown promise in other tumour types as a superior profiling method to understand abnormal tumour-related biological pathways. Translating this technology has potential in further subdividing glioblastoma tumours into distinct subtypes and thus could uncover previously unrecognizable treatment approaches.
As a medical researcher, I always strive to generate results that can positively affect patient outcomes and I am tremendously grateful for the generosity of the Motyka family and the Brain Tumour Foundation of Canada for their continued support of the brain tumour research field".
Susan Ruypers
Research Program Specialist
sruypers@braintumour.ca
1-800-265-5106 ext 240
Have you seen our blog lately? Read about people who are making a difference in the brain tumour community from our staff and volunteers to our donors, funded researchers, and medical experts. You will find advice, news, information, and interesting stories about people affected by a brain tumour. Who doesn't love a good story? You won't want to miss the inside scoop Grey Matters has in store for you!
Learn moreI had headaches, almost daily, for 10 years or more. It was a rare day if I did not have a headache. I used to joke that I should own...
Learn moreStability. It’s a strange concept when you have what it known to be a progressive, life long illness. You hear the words, “Your tumour...
Learn more